Turning breakthrough science into medicines.
Houston ranks third in the nation in academic R&D, but it only captures a fraction of the biotech value that science should produce, not because the science is lacking, but because breakthrough platforms have lacked the operational infrastructure to move from lab to clinic.
RBL Ventures closes that gap. We identify platforms, form companies, staff leadership, operate from day one with services exchanged for co-founder equity, so our incentives and our founders are one and the same.
How we are different
When RBL Ventures selects technology, we take an active role in forming the entity, structuring the equity, licensing the IP, recruiting leadership, running regulatory strategy, establishing manufacturing partnerships, and operating day-to-day.
This model is capital-efficient by design. Every RBL Ventures company operates from TMC Helix Park, sharing infrastructure, manufacturing relationships, and investor networks, each inherits a playbook that aims to significantly compress time to IND.
What we build around
RBL Ventures reviews projects based on their ability to target a condition with significant unmet need, genuinely differentiated science and platform-level potential.
We review many opportunities annually and form two to three companies per year. That selectivity is what allows our team to stay focused on execution.
To learn more about our process, reach out at: info@rbl-llc.com.
